Vyne Therapeutics has dosed the first participant in a randomised Phase Ib clinical trial of VYN202, an oral treatment for ...

Phase 1b trial designed to provide key insights into VYN202’s potential across a range of chronic, immune-mediated diseases BRIDGEWATER, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc.

A real-world study in Spain finds faster improvements with induction therapy but highlights long-term drug survival ...

Psoriasis was less likely to progress to psoriatic arthritis (PsA) among patients treated with interleukin-17 (IL-17) or ...

Bengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, has announced ...

The Department of Veterans Affairs (VA) saved $67 million in 2023 through its strong adoption of biosimilars to curb the high ...

The use of biologics in psoriasis and psoriatic arthritis management is not linked to the risk of cardiovascular or venous thromboembolic events.

STELLENBOSCH, WC - The State of South Africa’s Fathers 2024 report paints a not so good picture of what parenting is like in South Africa.

Biologics are more targeted than other psoriasis treatments. They’re also more expensive, and you take them less frequently. Doctors usually prescribe them for moderate to severe psoriasis.

Patients aged 55 years and older are more likely to discontinue biologic treatment for psoriasis due to adverse events, whereas patients aged 16 to 24 years are more likely to discontinue treatment of ...

Psoriasis is a chronic skin disease that manifests itself mainly with skin symptoms (dryness, itching, scaly skin, abnormal patches and plaques). It affects about 2% of the population and is mediated ...

Psoriatic arthritis (PsA) is a chronic inflammatory immune-mediated disease that affects approximately 30% of psoriasis patients. In most cases, skin disease clearly precedes the musculoskeletal ...